Ixmyelocel-T: SPA received

Aastrom received an SPA from FDA for the planned double-blind, placebo-controlled, U.S. Phase III REVIVE-CLI trial to evaluate ixmyelocel-T in up to 594 CLI patients with tissue loss. The company plan...